NEW YORK (GenomeWeb News) — Illumina today sent a third letter to shareholders urging them to turn away Roche's hostile bid for the company. At the same time, Roche expressed disappointment in Illumina's rebuff of its increased offer last week.

Illumina's annual shareholder meeting is scheduled for April 18, during which stockholders will elect four board members and vote on a proposal by Roche to expand the board by two members. Roche has named its own candidates for all open board positions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.